Mirati Therapeutics Inc (NASDAQ: MRTX), a clinical-stage targeted oncology company, has named Jenny Gizzi as its new vice president, Human Resources, it was reported yesterday.
Gizzi will report directly to Charles M Baum, MD, PhD, president and chief executive officer. In her role, she will be responsible for all aspects of the company's human resources operations and strategy, including managing the planning, development, implementation and administration of Mirati's human resources programs. She will also be responsible for long range human resources planning to assist Mirati with continued growth.
Gizzi joins Mirati Therapeutics with more than 20 years of experience in human resources, most recently serving as the head of Strategy & Operations, Business Insights and Analytics at Bristol-Myers Squibb. Earlier in her career at Bristol-Myers Squibb, Gizzi served as head of Human Resources for the Bay Area and Cambridge, and head of Global Talent for European Markets, Australia and Canada where her responsibilities included heading global talent for eight markets and 13 countries and leading the international team specialising in creation of overall talent strategy. Prior to her time at Bristol-Myers Squibb, she was head of Global Talent Acquisition for Illumina Inc where she was ultimately responsible for their talent function globally.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business